Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Shares of Tempus AI (TEM) are rising 5% in pre-market trading after surging 13% yesterday. The healthcare-focused AI stock ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Mac Cana brings the remarkable story of a Fermanagh doctor responsible for curing a type of cancer to the IMC in Enniskillen.

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Former Nickerson basketball star Ava Jones is speaking out about her cancer diagnosis months after a man was sentenced to ...

WICHITA, Kan. (KSNW) – Over the weekend, Ava Jones announced on Instagram that he had been diagnosed with cancer. On Thursday, Ava told KSN that she has Stage 4 Hodgkin’s Lymphoma. Coming up at 10, ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...